Changes in Beneficial Ownership · 4
Imunon, Inc.
IMNNNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
rdgdoc.xml
Filing details
- Report period
- 2026-08-28
- Issuer
- Imunon, Inc.
- Issuer CIK
- 0000749647
- Trading symbol
- IMNN
Reporting owner 1
- Name
- Eylward Susan
- Reporting owner CIK
- 0002039135
- Relationship
- Officer
- Officer title
- General Counsel and Corp Sec
- Address
- C/O IMUNON, INC., 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE, NJ, 08648
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-28 | A · Form 4 | 2,525[F1] | A | 1.60 | 5,421 | D |
| Common Stock | 2026-08-31 | S · Form 4 | 2,525 | D | 1.5643[F2] | 2,896 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Footnotes
- F1
- Stock granted in lieu of cash for portion of base salary↩ 1
- F2
- Reflects a weighted average sale price of $1.5643 per share, at prices ranging from $1.55 to $1.58 per share. The reporting person will provide, upon request by the staff of the Securities and Exchange Commission, the Company, or a security holder of the Company, full information regarding the number of shares sold at each separate price.↩ 1
Signature 1
- Signed
- /s/ Susan Eylward
- Date
- 2026-09-01
Company context
Imunon is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms with the aim to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. Imunon is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the coding of proteins and cytokines in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the coding of viral antigens that can elicit a strong immunological response. This technology may represent a promising platform for the development of vaccines in infectious diseases.
Current securities
Recent company filings
- S-1/A filingOct 28, 2026
- S-1 filingOct 27, 2026
- Other EventsOct 27, 2026
- Entry into a Material Definitive Agreement · Regulation FD DisclosureOct 21, 2026
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearSep 29, 2026